YAP1 Emerges as Key Driver of Small Cell Lung Cancer Relapse and Therapy Resistance
核心洞察
New research in the Journal of Thoracic Oncology identifies YAP1 (搜索) protein as a potential biomarker and therapeutic target for relapsed small cell lung cancer (搜索).
The study found YAP1 (搜索) emerges in tumors after chemotherapy, helping cancer cells survive, spread, and resist further treatment.
Lung Association-funded researcher Lauren Averett Byers, MD, of MD Anderson Cancer Center contributed to this work.
Small cell lung cancer (搜索) (SCLC) remains one of the most aggressive forms of lung cancer, notorious for its initial responsiveness to chemotherapy followed by near-inevitable relapse. New research published in the Journal of Thoracic Oncology now offers critical insights into the biological mechanisms driving this recurrence, identifying the protein YAP1 (搜索) as a central player in post-treatment tumor survival, metastasis, and therapy resistance.
The study sheds light on why SCLC often returns after initially responding to chemotherapy. Researchers discovered that YAP1 (搜索)—a transcriptional co-activator in the Hippo signaling pathway—emerges in tumors following chemotherapy exposure and appears to equip cancer cells with the ability to survive cytotoxic insult, disseminate to distant sites, and withstand subsequent lines of therapy.
Lung Association-funded researcher Lauren Averett Byers, MD, of the University of Texas MD Anderson Cancer Center, contributed to this work. The findings position YAP1 (搜索) as both a potential biomarker for identifying patients at high risk of relapse and a promising target for future therapeutic intervention in the relapsed setting.
The clinical implications are significant. SCLC accounts for approximately 10–15% of all lung cancers and carries a five-year survival rate that remains stubbornly low, particularly in extensive-stage disease. While most patients respond to first-line platinum-based chemotherapy, resistance typically develops within months, leaving limited effective options. Understanding the molecular underpinnings of this resistance is a critical unmet need in thoracic oncology.
The emergence of YAP1 (搜索) as a mediator of chemoresistance opens the door to combination strategies that could pair conventional chemotherapy with agents targeting the Hippo/YAP1 axis, potentially delaying or preventing relapse. Further preclinical and clinical investigation will be necessary to validate YAP1-targeted approaches and to determine whether YAP1 expression can serve as a reliable biomarker for treatment stratification.
This research was supported by the American Lung Association (搜索), which continues to fund innovative lung cancer research through its awards program, including the work of Dr. Byers at MD Anderson.